NCT07532590Recruiting
Patients With Pancreatic Tumor: Use of an App to Monitor Progress in a Simple and Intuitive Way by Periodically Completing Targeted Questionnaires and Providing Educational and Informational Content (PancreasPlus).
A Prospective Study on the Use of an App (PancreasPlus) for Home Monitoring and Proactive Management of Patients With Pancreatic Cancer.
Source: ClinicalTrials.gov · Last updated 11 May 2026
Brief summary (registry, in English)
Caring for people with pancreatic cancer requires good coordination between hospital care and care at home, with different healthcare professionals working closely together. Patients are also becoming more involved in managing their own care on a daily basis. However, this active involvement can be difficult if there is poor communication with healthcare teams, differences in skills or familiarity with digital tools, or systems that do not support patient participation. The PancreasPlus app was developed to support patients and caregivers by providing reliable information, self-monitoring tools, and a communication channel with healthcare professionals. The study aims to assess the feasibility, patient engagement, and perceived quality of routine use of the app. It is hypothesized that its use will improve engagement, perceived quality, reduce anxiety and unplanned hospital visits, without introducing technological or privacy risks. The app supports information and data collection but does not replace clinical decision-making. Objectives Primary objectives: Assess feasibility and patient engagement through questionnaire completion. Evaluate perceived service quality using the Client Satisfaction Questionnaire (CSQ-8). Secondary objectives: Monitor unplanned hospital visits and adherence to chemotherapy. Assess anxiety (HADS-A), nutritional status, and global quality of life (PROMIS Global). Evaluate usability and acceptability of the app (SUS, UTAUT2 short version). Endpoints Primary endpoints include questionnaire completion rates and perceived quality (CSQ-8 score). Secondary endpoints include unplanned hospital access, chemotherapy adherence, anxiety levels, nutritional status, quality of life, and app usability/acceptability. Methods This is a prospective, interventional, multicenter study with consecutive enrollment of eligible patients. Each participant will be followed for 3 months, with most activities conducted remotely via the app. At baseline (T0), patients receive study information, provide consent, undergo training, register in the app, and complete initial assessments (clinical, socio-demographic, PROMIS Global, HADS-A). At 12 weeks (W12), follow-up includes all outcome questionnaires and data on unplanned hospital visits. The app includes features such as a personal diary (symptoms, weight, BMI, appointments), interactive questionnaires with tailored feedback, and educational content on nutrition, prevention, emotional support, and patient rights. Population Inclusion criteria: adults (≥18 years) with pancreatic cancer, access to a smartphone/tablet (or caregiver support), ability to consent, and understanding of Italian. Exclusion criteria include severe cognitive impairment, inability to use the app or complete follow-up, or withdrawal of consent. Sample Size and Analysis A total of 185 patients will be enrolled (accounting for 10% dropout), based on an expected 70% engagement rate. Analyses will be conducted on both intention-to-observe and per-protocol populations. Engagement will be analyzed as questionnaire completion rates, while other outcomes will be analyzed using appropriate statistical models (e.g., logistic regression, ANCOVA, descriptive statistics). An interim analysis at 50% enrollment is planned to address potential low engagement.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 185 (estimated)
- First submitted
- 2 Apr 2026
- Start date
- 26 Feb 2026
- Primary completion date
- Mar 2027
- Lead sponsor
- Casa di Cura Dott. Pederzoli
- Diseases
- Pancreatic cancer
- NCT number
- NCT07532590
What you commit to
- Study type: Interventional
- Planned participants: 185
- From 26 Feb 2026 to the primary completion date, Mar 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe uncompensated cognitive impairment,
Other
- Social or logistical circumstances that prevent follow-up or access to/use of the app,
- Refusal or withdrawal of consent.
Who the study is looking for
- Age ≥18; diagnosis of pancreatic cancer (histological/cytological)
- Access to a smartphone or tablet and a data connection; basic digital literacy or a caregiver available,
- Ability to understand and provide informed consent; understanding of the Italian language.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| U.O. Chirurgia Generale 1, IRCCS San Matteo, Università degli Studi di Pavia Coordinator of this site? Confirm its status | Pavia | Italy | Active, not recruiting |
| Ospedale P. Pederzoli Casa di Cura Privata S.p.A. Coordinator of this site? Confirm its status | Peschiera del Garda | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.